{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:23:26Z","timestamp":1768983806200,"version":"3.49.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant mesothelioma (MMe) is an aggressive neoplasm that occurs through the transformation of mesothelial cells. Asbestos exposure is the main risk factor for MMe carcinogenesis. Other important etiologies for MMe development include DNA damage, over-activation of survival signaling pathways, and failure of DNA damage response (DDR). In this review article, first, we will describe the most important signaling pathways that contribute to MMe development and their interaction with DDR. Then, the contribution of DDR failure in MMe progression will be discussed. Finally, we will review the latest MMe therapeutic strategies that target the DDR pathway.<\/jats:p>","DOI":"10.1186\/s12935-022-02597-9","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T12:03:48Z","timestamp":1651493028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["DNA repair and damage pathways in mesothelioma development and therapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Faezeh","family":"Malakoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloufar","family":"Targhazeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erfan","family":"Abadifard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Zarezadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Samemaleki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zatollah","family":"Asemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Younesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Mohammadnejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed","family":"Hadi Hossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansar","family":"Karimian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forough","family":"Alemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4220-1527","authenticated-orcid":false,"given":"Bahman","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"issue":"1","key":"2597_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30227","volume":"29","author":"M Carbone","year":"2002","unstructured":"Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29(1):2\u201317.","journal-title":"Semin Oncol"},{"issue":"2","key":"2597_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.21873\/anticanres.13183","volume":"39","author":"SAS Salo","year":"2019","unstructured":"Salo SAS, Ilonen I, Laaksonen S, Myll\u00e4rniemi M, Salo JA, Rantanen T. Malignant peritoneal mesothelioma: treatment options and survival. Anticancer Res. 2019;39(2):839\u201345.","journal-title":"Anticancer Res"},{"issue":"142","key":"2597_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","volume":"25","author":"AC Bibby","year":"2016","unstructured":"Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472\u201386.","journal-title":"Eur Respir Rev"},{"key":"2597_CR4","doi-asserted-by":"publisher","first-page":"143631","DOI":"10.1016\/j.scitotenv.2020.143631","volume":"758","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun F, Chen H, Tan H, Yang L, Zhang L, Xie J, Sun J, Huang X, Huang Y. Postnatal exposure to DINP was associated with greater alterations of lipidomic markers for hepatic steatosis than DEHP in postweaning mice. Sci Total Environ. 2021;758:143631.","journal-title":"Sci Total Environ"},{"issue":"7","key":"2597_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413\u20139.","journal-title":"Carcinogenesis"},{"issue":"12","key":"2597_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/cancers11121839","volume":"11","author":"S Martinotti","year":"2019","unstructured":"Martinotti S, Patrone M, Moccia F, Ranzato E. Targeting calcium signalling in malignant mesothelioma. Cancers. 2019;11(12):1839.","journal-title":"Cancers"},{"issue":"3","key":"2597_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/genes6030500","volume":"6","author":"E Felley-Bosco","year":"2015","unstructured":"Felley-Bosco E, Opitz I, Meerang M. Hedgehog signaling in malignant pleural mesothelioma. Genes. 2015;6(3):500\u201311.","journal-title":"Genes"},{"issue":"6","key":"2597_CR8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","volume":"78","author":"JM Cleary","year":"2020","unstructured":"Cleary JM, Aguirre AJ, Shapiro GI, D\u2019Andrea AD. Biomarker-guided development of DNA repair inhibitors. Mol Cell. 2020;78(6):1070\u201385.","journal-title":"Mol Cell"},{"issue":"246","key":"2597_CR9","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.2002906","volume":"5","author":"DJ Robbins","year":"2012","unstructured":"Robbins DJ, Fei DL, Riobo NA. The Hedgehog signal transduction network. Sci Signal. 2012;5(246):re6.","journal-title":"Sci Signal"},{"issue":"1","key":"2597_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J Basic Med Sci. 2018;18(1):8\u201320.","journal-title":"Bosn J Basic Med Sci"},{"issue":"6","key":"2597_CR11","doi-asserted-by":"publisher","first-page":"e66685","DOI":"10.1371\/journal.pone.0066685","volume":"8","author":"CB Lim","year":"2013","unstructured":"Lim CB, Pr\u00eale CM, Cheah HM, Cheng YY, Klebe S, Reid G, Watkins DN, Baltic S, Thompson PJ, Mutsaers SE. Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. PLoS ONE. 2013;8(6):e66685.","journal-title":"PLoS ONE"},{"issue":"2","key":"2597_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/cells8020147","volume":"8","author":"P Niewiadomski","year":"2019","unstructured":"Niewiadomski P, Niedzi\u00f3\u0142ka SM, Markiewicz \u0141, U\u015bpie\u0144ski T, Baran B, Chojnowska K. Gli proteins: regulation in development and cancer. Cells. 2019;8(2):147.","journal-title":"Cells"},{"issue":"21","key":"2597_CR13","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1242\/dev.098079","volume":"140","author":"R Dixit","year":"2013","unstructured":"Dixit R, Ai X, Fine A. Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry. Development. 2013;140(21):4398\u2013406.","journal-title":"Development"},{"issue":"17","key":"2597_CR14","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1158\/1078-0432.CCR-12-0599","volume":"18","author":"Y Shi","year":"2012","unstructured":"Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, Weder W, Stahel RA, Felley-Bosco E. Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res: Official J American Association Cancer Res. 2012;18(17):4646\u201356.","journal-title":"Clin Cancer Res: Official J American Association Cancer Res"},{"issue":"1","key":"2597_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1756-9966-32-7","volume":"32","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013;32(1):7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2597_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1158\/0008-5472.CAN-11-2681","volume":"72","author":"E Heller","year":"2012","unstructured":"Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72(4):897\u2013907.","journal-title":"Cancer Res"},{"issue":"5","key":"2597_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-15-0583","volume":"15","author":"M Meerang","year":"2016","unstructured":"Meerang M, B\u00e9rard K, Felley-Bosco E, Lauk O, Vrugt B, Boss A, Kenkel D, Broggini-Tenzer A, Stahel RA, Arni S, et al. Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in vivo by affecting stroma. Mol Cancer Ther. 2016;15(5):1095\u2013105.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2597_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Can Res. 2011;71(3):873\u201383.","journal-title":"Can Res"},{"issue":"1","key":"2597_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jtcvs.2013.08.035","volume":"147","author":"M You","year":"2014","unstructured":"You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2014;147(1):508\u201316.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"2597_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/cgt.2015.31","volume":"22","author":"HA Kim","year":"2015","unstructured":"Kim HA, Kim MC, Kim NY, Kim Y. Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines. Cancer Gene Ther. 2015;22(8):387\u201395.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2597_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jcp.30573","volume":"237","author":"F Alemi","year":"2022","unstructured":"Alemi F, Raei Sadigh A, Malakoti F, Elhaei Y, Ghaffari SH, Maleki M, Asemi Z, Yousefi B, Targhazeh N, Majidinia M. Molecular mechanisms involved in DNA repair in human cancers: an overview of PI3k\/Akt signaling and PIKKs crosstalk. J Cell Physiol. 2022;237(1):313\u201328.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2597_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471\u201384.","journal-title":"Cell"},{"key":"2597_CR23","doi-asserted-by":"publisher","first-page":"32992","DOI":"10.1038\/srep32992","volume":"6","author":"R Kanteti","year":"2016","unstructured":"Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R. PI3 kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma. Sci Rep. 2016;6:32992.","journal-title":"Sci Rep"},{"issue":"15","key":"2597_CR24","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1016\/j.ejca.2010.06.130","volume":"46","author":"F Perrone","year":"2010","unstructured":"Perrone F, Jocoll\u00e8 G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, et al. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer. 2010;46(15):2837\u201348.","journal-title":"Eur J Cancer"},{"issue":"22","key":"2597_CR25","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.3390\/ijms20225817","volume":"20","author":"A Belfiore","year":"2019","unstructured":"Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, et al. Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma. Int J Mol Sci. 2019;20(22):5817.","journal-title":"Int J Mol Sci"},{"key":"2597_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.08.019","volume":"97","author":"L Urso","year":"2016","unstructured":"Urso L, Calabrese F, Favaretto A, Conte P, Pasello G. Critical review about MDM2 in cancer: possible role in malignant mesothelioma and implications for treatment. Crit Rev Oncol Hematol. 2016;97:220\u201330.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2597_CR27","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"S Zhou","year":"2014","unstructured":"Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, et al. Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer. 2014;110(10):2479\u201388.","journal-title":"Br J Cancer"},{"issue":"1","key":"2597_CR28","doi-asserted-by":"publisher","first-page":"e000101","DOI":"10.1136\/esmoopen-2016-000101","volume":"2","author":"SO Dolly","year":"2017","unstructured":"Dolly SO, Migali C, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, de Bono JS, Kaye SB, Banerjee S. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ESMO open. 2017;2(1):e000101.","journal-title":"ESMO open"},{"issue":"9","key":"2597_CR29","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","volume":"9","author":"R Kanteti","year":"2014","unstructured":"Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, et al. MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS ONE. 2014;9(9):e105919.","journal-title":"PLoS ONE"},{"issue":"11","key":"2597_CR30","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.21873\/anticanres.13833","volume":"39","author":"A Kuroda","year":"2019","unstructured":"Kuroda A, Matsumoto S, Fukuda A, Nakamichi T, Nakamura A, Hashimoto M, Takuwa T, Kondo N, Tsujimura T, Nakano T, et al. The mTOR signaling pathway is associated with the prognosis of malignant pleural mesothelioma after multimodality therapy. Anticancer Res. 2019;39(11):6241\u20137.","journal-title":"Anticancer Res"},{"issue":"4","key":"2597_CR31","doi-asserted-by":"publisher","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","volume":"6","author":"DA Altomare","year":"2011","unstructured":"Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, Neumann-Domer E, Liu Z, Carbone M, Chudoba I, et al. Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS ONE. 2011;6(4):e18828.","journal-title":"PLoS ONE"},{"issue":"8","key":"2597_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","volume":"19","author":"MA Bonelli","year":"2017","unstructured":"Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, et al. Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 2017;19(8):637\u201348.","journal-title":"Neoplasia"},{"issue":"5","key":"2597_CR33","doi-asserted-by":"publisher","first-page":"e1757","DOI":"10.1038\/cddis.2015.124","volume":"6","author":"N Echeverry","year":"2015","unstructured":"Echeverry N, Ziltener G, Barbone D, Weder W, Stahel RA, Broaddus VC, Felley-Bosco E. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors. Cell Death Dis. 2015;6(5):e1757.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2597_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/ijms23010370","volume":"23","author":"L Garc\u00eda-Hern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Hern\u00e1ndez L, Garc\u00eda-Ortega MB, Ruiz-Alcal\u00e1 G, Carrillo E, Marchal JA, Garc\u00eda M. The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci. 2021;23(1):370.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2597_CR35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00204-015-1472-2","volume":"89","author":"EK Kim","year":"2015","unstructured":"Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867\u201382.","journal-title":"Arch Toxicol"},{"key":"2597_CR36","doi-asserted-by":"publisher","first-page":"118123","DOI":"10.1016\/j.lfs.2020.118123","volume":"257","author":"M Gandhi","year":"2020","unstructured":"Gandhi M, Nair S. New vistas in malignant mesothelioma: MicroRNA architecture and NRF2\/MAPK signal transduction. Life Sci. 2020;257:118123.","journal-title":"Life Sci"},{"issue":"8","key":"2597_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bbamcr.2007.01.002","volume":"1773","author":"M Katz","year":"2007","unstructured":"Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007;1773(8):1161\u201376.","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"2597_CR38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1289\/ehp.10924","volume":"116","author":"M Pacurari","year":"2008","unstructured":"Pacurari M, Yin XJ, Zhao J, Ding M, Leonard SS, Schwegler-Berry D, Ducatman BS, Sbarra D, Hoover MD, Castranova V, et al. Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells. Environ Health Perspect. 2008;116(9):1211\u20137.","journal-title":"Environ Health Perspect"},{"issue":"2","key":"2597_CR39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.bjc.6605467","volume":"102","author":"D Johansson","year":"2010","unstructured":"Johansson D, Andersson C, Moharer J, Johansson A, Behnam-Motlagh P. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. Br J Cancer. 2010;102(2):383\u201391.","journal-title":"Br J Cancer"},{"issue":"2","key":"2597_CR40","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2009;2(2):181\u20138.","journal-title":"Mol Med Rep"},{"issue":"14","key":"2597_CR41","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.3390\/ijms21145165","volume":"21","author":"M Bonelli","year":"2020","unstructured":"Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, Alfieri R, Cavazzoni A, Digiacomo G, Galetti M, et al. Dual inhibition of CDK4\/6 and PI3K\/AKT\/mTOR signaling impairs energy metabolism in MPM cancer cells. Int J Mol Sci. 2020;21(14):5165.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2597_CR42","doi-asserted-by":"publisher","first-page":"10070","DOI":"10.1038\/s41598-018-28297-x","volume":"8","author":"C Li","year":"2018","unstructured":"Li C, Rezov V, Joensuu E, Vartiainen V, R\u00f6nty M, Yin M, Myll\u00e4rniemi M, Koli K. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo. Sci Rep. 2018;8(1):10070.","journal-title":"Sci Rep"},{"key":"2597_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcancer.2018.01.006","volume":"54","author":"CK Rane","year":"2019","unstructured":"Rane CK, Minden A. P21 activated kinase signaling in cancer. Semin Cancer Biol. 2019;54:40\u20139.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2597_CR44","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1158\/1541-7786.MCR-12-0082","volume":"10","author":"CW Menges","year":"2012","unstructured":"Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR, Testa JR. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res. 2012;10(9):1178\u201388.","journal-title":"Mol Cancer Res"},{"issue":"10","key":"2597_CR45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2174\/1381612825666190506122228","volume":"25","author":"S Chen","year":"2019","unstructured":"Chen S, Li F, Xu D, Hou K, Fang W, Li Y. The function of RAS mutation in cancer and advances in its drug research. Curr Pharm Des. 2019;25(10):1105\u201314.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"2597_CR46","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/JTO.0b013e31811f3aab","volume":"2","author":"MR Patel","year":"2007","unstructured":"Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA. Ras pathway activation in malignant mesothelioma. J Thorac Oncol: Official Publication Int Association Study Lung Cancer. 2007;2(9):789\u201395.","journal-title":"J Thorac Oncol: Official Publication Int Association Study Lung Cancer"},{"issue":"6","key":"2597_CR47","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.molcel.2020.04.017","volume":"78","author":"S Marchi","year":"2020","unstructured":"Marchi S, Giorgi C, Galluzzi L, Pinton P. Ca(2+) fluxes and cancer. Mol Cell. 2020;78(6):1055\u201369.","journal-title":"Mol Cell"},{"key":"2597_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.lfs.2016.01.048","volume":"148","author":"C Marchetti","year":"2016","unstructured":"Marchetti C, Ribulla S, Magnelli V, Patrone M, Burlando B. Resveratrol induces intracellular Ca(2+) rise via T-type Ca(2+) channels in a mesothelioma cell line. Life Sci. 2016;148:125\u201331.","journal-title":"Life Sci"},{"issue":"2","key":"2597_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0344-0338(96)80208-1","volume":"192","author":"V Gotzos","year":"1996","unstructured":"Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract. 1996;192(2):137\u201347.","journal-title":"Pathol Res Pract"},{"key":"2597_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12931-015-0311-6","volume":"16","author":"W Blum","year":"2015","unstructured":"Blum W, Pecze L, Felley-Bosco E, Schwaller B. Overexpression or absence of calretinin in mouse primary mesothelial cells inversely affects proliferation and cell migration. Respir Res. 2015;16:153.","journal-title":"Respir Res"},{"issue":"2","key":"2597_CR51","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/ijms20020429","volume":"20","author":"A Guazzelli","year":"2019","unstructured":"Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, Mutti L. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci. 2019;20(2):429.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2597_CR52","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1165\/ajrcmb.19.2.3111","volume":"19","author":"N Choe","year":"1998","unstructured":"Choe N, Tanaka S, Kagan E. Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol. 1998;19(2):226\u201336.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2597_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","volume":"160","author":"NS Gavande","year":"2016","unstructured":"Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: the past or future of cancer treatment? Pharmacol Ther. 2016;160:65\u201383.","journal-title":"Pharmacol Ther"},{"key":"2597_CR54","doi-asserted-by":"publisher","first-page":"103036","DOI":"10.1016\/j.dnarep.2020.103036","volume":"98","author":"F Malakoti","year":"2021","unstructured":"Malakoti F, Alemi F, Younesi S, Majidinia M, Yousefi B, Morovat P, Khelghati N, Maleki M, Karimian A, Asemi Z. The cross-talk between signaling pathways, noncoding RNAs and DNA damage response: emerging players in cancer progression. DNA Repair. 2021;98:103036.","journal-title":"DNA Repair"},{"key":"2597_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2019.03.001","volume":"781","author":"M Betti","year":"2019","unstructured":"Betti M, Aspesi A, Sculco M, Matullo G, Magnani C, Dianzani I. Genetic predisposition for malignant mesothelioma: a concise review. Mutat Res. 2019;781:1\u201310.","journal-title":"Mutat Res"},{"issue":"28","key":"2597_CR56","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol\u202f: Official J American Society Clin Oncol. 2018;36(28):2863\u201371.","journal-title":"J Clin Oncol : Official J American Society Clin Oncol"},{"issue":"12","key":"2597_CR57","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.3390\/ijms21124327","volume":"21","author":"V Panou","year":"2020","unstructured":"Panou V, R\u00f8e OD. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int J Mol Sci. 2020;21(12):4327.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2597_CR58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1042\/EBC20200013","volume":"64","author":"GJ Grundy","year":"2020","unstructured":"Grundy GJ, Parsons JL. Base excision repair and its implications to cancer therapy. Essays Biochem. 2020;64(5):831\u201343.","journal-title":"Essays Biochem"},{"issue":"2","key":"2597_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13277-015-3054-6","volume":"36","author":"CJ Qin","year":"2015","unstructured":"Qin CJ, Xu KW, Chen ZH, Zhai ET, He YL, Song XM. XRCC1 R399Q polymorphism and colorectal cancer risk in the Chinese Han population: a meta-analysis. Tumour Biol. 2015;36(2):461\u20136.","journal-title":"Tumour Biol"},{"key":"2597_CR60","doi-asserted-by":"publisher","first-page":"153303382110330","DOI":"10.1177\/15330338211033060","volume":"20","author":"S Xia","year":"2021","unstructured":"Xia S, Wu S, Wang M. The association between the XRCC1 Arg399Gln polymorphism and the risk of head and neck cancer: an updated meta-analysis including 14586 subjects. Technol Cancer Res Treat. 2021;20:15330338211033060.","journal-title":"Technol Cancer Res Treat"},{"issue":"1\u20132","key":"2597_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mrfmmm.2011.01.001","volume":"708","author":"M Betti","year":"2011","unstructured":"Betti M, Ferrante D, Padoan M, Guarrera S, Giordano M, Aspesi A, Mirabelli D, Casadio C, Ardissone F, Ruffini E, et al. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study. Mutat Res. 2011;708(1\u20132):11\u201320.","journal-title":"Mutat Res"},{"issue":"6","key":"2597_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0960-9822(06)00190-4","volume":"7","author":"G Weeda","year":"1997","unstructured":"Weeda G, Donker I, de Wit J, Morreau H, Janssens R, Vissers CJ, Nigg A, van Steeg H, Bootsma D, Hoeijmakers JH. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Current Biol. 1997;7(6):427\u201339.","journal-title":"Current Biol"},{"issue":"2","key":"2597_CR63","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2478\/raon-2019-0016","volume":"53","author":"K Levpuscek","year":"2019","unstructured":"Levpuscek K, Goricar K, Kovac V, Dolzan V, Franko A. The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma. Radiol Oncol. 2019;53(2):206\u201312.","journal-title":"Radiol Oncol"},{"issue":"10","key":"2597_CR64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2597_CR65","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2011.08.021","volume":"312","author":"D Toumpanakis","year":"2011","unstructured":"Toumpanakis D, Theocharis SE. DNA repair systems in malignant mesothelioma. Cancer Lett. 2011;312(2):143\u20139.","journal-title":"Cancer Lett"},{"issue":"5","key":"2597_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/mutage\/ger020","volume":"26","author":"M Tomasetti","year":"2011","unstructured":"Tomasetti M, Amati M, Nocchi L, Saccucci F, Strafella E, Staffolani S, Tarquini LM, Carbonari D, Alleva R, Borghi B, et al. Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis. 2011;26(5):585\u201391.","journal-title":"Mutagenesis"},{"key":"2597_CR67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.dnarep.2015.11.019","volume":"38","author":"Z Li","year":"2016","unstructured":"Li Z, Pearlman AH, Hsieh P. DNA mismatch repair and the DNA damage response. DNA Repair. 2016;38:94\u2013101.","journal-title":"DNA Repair"},{"key":"2597_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","volume":"189","author":"M Baretti","year":"2018","unstructured":"Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45\u201362.","journal-title":"Pharmacol Ther"},{"key":"2597_CR69","doi-asserted-by":"publisher","first-page":"102101","DOI":"10.1016\/j.ctrv.2020.102101","volume":"90","author":"I Fuso Nerini","year":"2020","unstructured":"Fuso Nerini I, Roca E, Mannarino L, Grosso F, Frapolli R, D\u2019Incalci M. Is DNA repair a potential target for effective therapies against malignant mesothelioma? Cancer Treat Rev. 2020;90:102101.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"2597_CR70","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.molcel.2021.05.010","volume":"81","author":"L Dai","year":"2021","unstructured":"Dai L, Dai Y, Han J, Huang Y, Wang L, Huang J, Zhou Z. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021;81(13):2765-2777.e2766.","journal-title":"Mol Cell"},{"issue":"3","key":"2597_CR71","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"M Cheung","year":"2017","unstructured":"Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res. 2017;6(3):270\u20138.","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"2597_CR72","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372.","journal-title":"Nat Genet"},{"issue":"11","key":"2597_CR73","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","volume":"8","author":"MG Zauderer","year":"2013","unstructured":"Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol: Official Publication Int Association Study Lung Cancer. 2013;8(11):1430\u20133.","journal-title":"J Thorac Oncol: Official Publication Int Association Study Lung Cancer"},{"issue":"1","key":"2597_CR74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","volume":"20","author":"L Arzt","year":"2014","unstructured":"Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res. 2014;20(1):145\u201351.","journal-title":"Pathol Oncol Res"},{"issue":"5","key":"2597_CR75","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","volume":"103","author":"Y Yoshikawa","year":"2012","unstructured":"Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103(5):868\u201374.","journal-title":"Cancer Sci"},{"issue":"4","key":"2597_CR76","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol: Official Publication Int Association Study Lung Cancer. 2015;10(4):565\u201376.","journal-title":"J Thorac Oncol: Official Publication Int Association Study Lung Cancer"},{"issue":"8","key":"2597_CR77","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495\u2013506.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2597_CR78","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1073\/pnas.0712399105","volume":"105","author":"DJ Sugarbaker","year":"2008","unstructured":"Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G, Glickman JN, Chirieac LR, Hartman ML, Taillon BE, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci USA. 2008;105(9):3521\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2597_CR79","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G. Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479\u201395.","journal-title":"Eur Respir J"},{"issue":"4","key":"2597_CR80","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","volume":"80","author":"G Srinivasan","year":"2017","unstructured":"Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ Jr, Hromas R. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017;80(4):861\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2597_CR81","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","volume":"15","author":"D Rathkey","year":"2020","unstructured":"Rathkey D, Khanal M, Murai J, Zhang J, Sengupta M, Jiang Q, Morrow B, Evans CN, Chari R, Fetsch P, et al. Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and Low-O6-methylguanine-DNA methyltransferase expression. J Thorac Oncol: Official Publication Int Association Study Lung Cancer. 2020;15(5):843\u201359.","journal-title":"J Thorac Oncol: Official Publication Int Association Study Lung Cancer"},{"key":"2597_CR82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2019.07.011","volume":"135","author":"F Morra","year":"2019","unstructured":"Morra F, Merolla F, D\u2019Abbiero D, Ilardi G, Campione S, Monaco R, Guggino G, Ambrosio F, Staibano S, Cerrato A. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma. Lung Cancer. 2019;135:56\u201365.","journal-title":"Lung Cancer"},{"issue":"5","key":"2597_CR83","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","volume":"15","author":"D Rathkey","year":"2020","unstructured":"Rathkey D, Khanal M, Murai J, Zhang J, Sengupta M, Jiang Q, Morrow B, Evans CN, Chari R, Fetsch P. Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression. J Thorac Oncol. 2020;15(5):843.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2597_CR84","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jcmm.12000","volume":"17","author":"G Pinton","year":"2013","unstructured":"Pinton G, Manente AG, Murer B, De Marino E, Mutti L, Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT\/mTOR axis via SIRT1. J Cell Mol Med. 2013;17(2):233\u201341.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2597_CR85","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/mutage\/ger020","volume":"26","author":"M Tomasetti","year":"2011","unstructured":"Tomasetti M, Amati M, Nocchi L, Saccucci F, Strafella E, Staffolani S, Tarquini LM, Carbonari D, Alleva R, Borghi B. Asbestos exposure affects poly (ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis. 2011;26(5):585\u201391.","journal-title":"Mutagenesis"},{"issue":"3","key":"2597_CR86","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1527-3466.2007.00018.x","volume":"25","author":"P Pacher","year":"2007","unstructured":"Pacher P, Szab\u00f3 C. Role of poly (ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007;25(3):235\u201360.","journal-title":"Cardiovasc Drug Rev"},{"issue":"182","key":"2597_CR87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1126\/scisignal.2001465","volume":"4","author":"NR Sundaresan","year":"2011","unstructured":"Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Science signaling. 2011;4(182):46.","journal-title":"Science signaling"},{"issue":"2","key":"2597_CR88","doi-asserted-by":"publisher","first-page":"e9199","DOI":"10.1371\/journal.pone.0009199","volume":"5","author":"HS Ghosh","year":"2010","unstructured":"Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS ONE. 2010;5(2):e9199.","journal-title":"PLoS ONE"},{"issue":"1","key":"2597_CR89","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","volume":"19","author":"S Borchert","year":"2019","unstructured":"Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RF. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;19(1):108.","journal-title":"BMC Cancer"},{"issue":"4","key":"2597_CR90","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","volume":"44","author":"M Tavecchio","year":"2008","unstructured":"Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D\u2019Incalci M, Damia G. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer. 2008;44(4):609\u201318.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2597_CR91","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/ijc.28213","volume":"133","author":"M Romano","year":"2013","unstructured":"Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, Garc\u00eda-Fern\u00e1ndez LF, Cuevas C, Allavena P, Erba E. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis\u00ae(PM00104). Int J Cancer. 2013;133(9):2024\u201333.","journal-title":"Int J Cancer"},{"issue":"4","key":"2597_CR92","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","volume":"77","author":"AK Larsen","year":"2016","unstructured":"Larsen AK, Galmarini CM, D\u2019Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016;77(4):663\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2597_CR93","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","volume":"9","author":"S Arora","year":"2010","unstructured":"Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM. Downregulation of XPF\u2013ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair. 2010;9(7):745\u201353.","journal-title":"DNA Repair"},{"issue":"13","key":"2597_CR94","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1158\/1078-0432.CCR-07-0252","volume":"13","author":"A Handra-Luca","year":"2007","unstructured":"Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria J-C, Fouret P. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(13):3855\u20139.","journal-title":"Clin Cancer Res"},{"issue":"32","key":"2597_CR95","doi-asserted-by":"publisher","first-page":"13062","DOI":"10.1073\/pnas.0609877104","volume":"104","author":"DG Soares","year":"2007","unstructured":"Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JAP, Larsen AK. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci. 2007;104(32):13062\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"2597_CR96","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ygyno.2014.03.119","volume":"133","author":"B Monk","year":"2014","unstructured":"Monk B, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park Y, Ricci D, Poveda A. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study. Gynecol Oncol. 2014;133:41.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2597_CR97","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/annonc\/mdu134","volume":"25","author":"S Delaloge","year":"2014","unstructured":"Delaloge S, Wolp-Diniz R, Byrski T, Blum J, Gon\u00e7alves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M. Activity of trabectedin in germline BRCA1\/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol. 2014;25(6):1152\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"2597_CR98","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/bjc.2014.149","volume":"111","author":"M D\u2019incalci","year":"2014","unstructured":"D\u2019incalci M, Badri N, Galmarini C, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111(4):646\u201350.","journal-title":"Br J Cancer"},{"issue":"2","key":"2597_CR99","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249\u201362.","journal-title":"Cancer Cell"},{"key":"2597_CR100","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.compbiomed.2021.105092","volume":"140","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Cui F, Cao C, Wang Q, Zou Q. Single-cell RNA analysis reveals the potential risk of organ-specific cell types vulnerable to SARS-CoV-2 infections. Comput Biol Med. 2022;140:105092.","journal-title":"Comput Biol Med"},{"issue":"10","key":"2597_CR101","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","volume":"13","author":"S Arulananda","year":"2018","unstructured":"Arulananda S, Thapa B, Walkiewicz M, Zapparoli GV, Williams DS, Dobrovic A, John T. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1588\u201394.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2597_CR102","first-page":"1157","volume":"55","author":"L Losi","year":"2019","unstructured":"Losi L, Bertolini F, Guaitoli G, Fabbiani L, Banchelli F, Ambrosini-Spaltro A, Botticelli L, Scurani L, Baldessari C, Barbieri F. Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. Int J Oncol. 2019;55(5):1157\u201364.","journal-title":"Int J Oncol"},{"issue":"16","key":"2597_CR103","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","volume":"74","author":"IH Ismail","year":"2014","unstructured":"Ismail IH, Davidson R, Gagn\u00e9 J-P, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Can Res. 2014;74(16):4282\u201394.","journal-title":"Can Res"},{"issue":"7","key":"2597_CR104","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D\u2019Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675\u201393.","journal-title":"Cancer Discov"},{"issue":"1","key":"2597_CR105","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","volume":"11","author":"R Shrestha","year":"2019","unstructured":"Shrestha R, Nabavi N, Lin Y, Mo F, Anderson S, Volik S. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019;11(1):8.","journal-title":"Genome Med"},{"key":"2597_CR106","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley K, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb E. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365. https:\/\/doi.org\/10.1158\/2159-8290.","journal-title":"Cancer Discov"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02597-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:17:02Z","timestamp":1651497422000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02597-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02597-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We agree to the publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}